Aclaris Therap | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 3.299 M

Revenue: As of FY2025 Q3, the actual value is USD 3.299 M, beating the estimate of USD 1.405 M.

EPS: As of FY2025 Q3, the actual value is USD -0.12, beating the estimate of USD -0.135.

EBIT: As of FY2025 Q3, the actual value is USD -18.97 M.

Financial Results Summary

Segment Revenue

• Total revenue for the third quarter of 2025 was $3.3 million, compared to $4.3 million for the third quarter of 2024. For the nine months ended September 30, 2025, total revenue was $6.5 million, compared to $9.5 million for the same period in 2024. The decrease was primarily due to larger milestones achieved under the Sun Pharma license agreement in 2024 and higher licensing revenue under the Eli Lilly license agreement.

Operational Metrics

• Net loss for the third quarter of 2025 was $14.6 million, compared to $7.6 million for the third quarter of 2024. For the nine months ended September 30, 2025, net loss was $45.1 million, compared to $35.5 million for the same period in 2024.
• Research and development expenses were $13.0 million for the third quarter of 2025, compared to $6.0 million for the same period in 2024. For the nine months ended September 30, 2025, R&D expenses were $36.1 million, compared to $24.6 million for the same period in 2024.
• General and administrative expenses were $4.9 million for the third quarter of 2025, compared to $5.7 million for the same period in 2024. For the nine months ended September 30, 2025, G&A expenses were $16.4 million, compared to $17.2 million for the same period in 2024.

Cash Flow

• As of September 30, 2025, Aclaris had cash, cash equivalents, and marketable securities of $167.2 million, compared to $203.9 million as of December 31, 2024.
• Net cash used in operating activities was - $33.9 million for the nine months ended September 30, 2025, compared to - $11.1 million for the same period in 2024.

Outlook / Guidance

• Aclaris expects its cash, cash equivalents, and marketable securities to fund operations into the second half of 2028. The company is also exploring non-dilutive opportunities to extend its cash runway further.